A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers

Inclusion Criteria: * Male participants and their partners of child-bearing potential must be willing to use two effective contraceptive methods * Female participants must be either postmenopausal or surgically sterile * Intact normal skin in the area for intended injection * Body weight less than (\<) 150 kilograms (kg) * Have no contraindications from the following: a detailed medical and surgical history, a complete physical examination, including vital signs, 12-lead electro cardio gram (ECG), hematology, blood chemistry, serology, and urinalysis Exclusion Criteria: * Participants with any known active current or history of recurrent Infectious disease * Positive result on hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus-1 (HIV-1) and HIV-2 at screening * A history of clinically significant gastrointestinal, renal, hepatic, cardiovascular, or allergic disease * Evidence of malignant disease, or malignancies diagnosed within the previous 5 years * Use of or being dependent within the last 12 months on any substances of abuse, including a relevant past history of alcohol abuse * Participants with a history of, or currently active primary or secondary immunodeficiency * Participants who smoke more than 10 cigarettes per day or equivalent in tobacco * Clinically relevant deviation from normal in the physical examination, including vital signs * Clinically relevant ECG abnormalities on screening * Evidence of atrial fibrillation, atrial flutter, right or left bundle branch block, Wolf-Parkinson-White syndrome, or cardiac pacemaker or any other significant cardiac abnormalities * Known allergy to TCZ or any other ingredient in the subcutaneous (SC) formulation * History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies * Known coagulopathy * Clinically significant abnormalities in laboratory test results * Immunization with a live or attenuated vaccine is prohibited within 4 weeks prior to study drug administration